We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Oncosil Medical Ltd | ASX:OSL | Australian Stock Exchange | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.007 | 0.008 | 0.007 | 0.00 | 20:00:43 |
RNS Number:3747L Sharp (James) & Co 21 May 2003 Date of Disclosure 21ST MAY 2003 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3 OF THE CITY CODE ON TAKEOVERS AND MERGERS Date of dealing 21ST MAY 2003 Dealing in OSBORNE & LITTLE PLC (name of company) 1) Class of securities (eg ordinary shares) ORDINARY SHARES GBP 0.05 2) Amount bought Amount sold Price per unit 1,300 190P 3) Resultant total of the same class owned or controlled (and percentage of class) 200,000 SHARES (3.32%) 4) Party making disclosure JAMES SHARP & CO 5) EITHER (a) Name of purchaser/vendor (Note 1) LYNNIG LIMITED OR (b) if dealing for discretionary client(s), name of fund management organisation 6) Reason for disclosure (Note 2) (a) associate of (i) offeror (Note 3) NO (ii) offeree company NO Specify which category or categories of associate (1-8 overleaf) If category (8), explain (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more of the class of relevant securities dealt in) YES Signed, for and on behalf of the party named in (4) above N/A (Also print name of signatory) MICHAEL TULIP Telephone and extension number 0161 764 4043 Note 1. Specify owner, not nominee or vehicle company. If relevant, also identify controller of owner, eg where an owner normally acts on instructions of a controller Note 2. Disclosure might be made for more than one reason; if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree company or which an associate of any offeror or of the offeree company in relation to relevant securities, details of such arrangement must be disclosed, as required by Note 6 on Rule 8 Note 5. It may be necessary, particularly when disclosing derivative transactions, to append a sheet to this disclosure form so that relevant information can be given. Note 6. In the case of an average price bargain, each underlying trade should be disclosed. For full details of disclosure requirements, see Rule 8 of the Code. If in doubt, contact the Panel on Takeovers and Mergers, Tel No: 020 7382 9026 Date of Disclosure 21ST MAY 2003 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) and 8.3 OF THE CITY CODE ON TAKEOVERS AND MERGERS Date of dealing 20TH MAY 2003 Dealing in OSBORNE & LITTLE PLC (name of company) 1) Class of securities (eg ordinary shares) ORDINARY SHARES GBP 0.05 2) Amount bought Amount sold Price per unit 15,000 190P 3) Resultant total of the same class owned or controlled (and percentage of class) 198,700 SHARES (3.29%) 4) Party making disclosure JAMES SHARP & CO 5) EITHER (a) Name of purchaser/vendor (Note 1) LYNNIG LIMITED OR (b) if dealing for discretionary client(s), name of fund management organisation 6) Reason for disclosure (Note 2) (a) associate of (i) offeror (Note 3) NO (ii) offeree company NO Specify which category or categories of associate (1-8 overleaf) If category (8), explain (b) Rule 8.3 (ie disclosure because of ownership or control of 1% or more of the class of relevant securities dealt in) YES Signed, for and on behalf of the party named in (4) above N/A (Also print name of signatory) MICHAEL TULIP Telephone and extension number 0161 764 4043 Note 1. Specify owner, not nominee or vehicle company. If relevant, also identify controller of owner, eg where an owner normally acts on instructions of a controller Note 2. Disclosure might be made for more than one reason; if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note 4. When an arrangement exists with any offeror, with the offeree company or which an associate of any offeror or of the offeree company in relation to relevant securities, details of such arrangement must be disclosed, as required by Note 6 on Rule 8 Note 5. It may be necessary, particularly when disclosing derivative transactions, to append a sheet to this disclosure form so that relevant information can be given. Note 6. In the case of an average price bargain, each underlying trade should be disclosed. For full details of disclosure requirements, see Rule 8 of the Code. If in doubt, contact the Panel on Takeovers and Mergers, Tel No: 020 7382 9026 This information is provided by RNS The company news service from the London Stock Exchange END DCCFGGZKMMFGFZM
1 Year Oncosil Medical Chart |
1 Month Oncosil Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions